Cardiovascular Complications of Cancer Therapeutics

2010 ◽  
pp. 87-115
Author(s):  
Aarif Y. Khakoo ◽  
Callie S. Kwartler
Keyword(s):  
Cancer Therapeutics ◽  
Cardiovascular Complications

Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment

2019 ◽  
Vol 24 (37) ◽  
pp. 4424-4435 ◽  
Author(s):  
Evangelos Oikonomou ◽  
Μaria Anastasiou ◽  
Gerasimos Siasos ◽  
Emmanuel Androulakis ◽  
Amanda Psyrri ◽  
...  
Keyword(s):  
Cancer Therapeutics ◽  
Cardiovascular Complications ◽  
Diagnosis And Treatment

scholarly journals Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors

2021 ◽  
Vol 28 (5) ◽  
pp. 4139-4156
Author(s):  
Sonu S. Varghese ◽  
Will J. Johnston ◽  
Cameron R. Eekhoudt ◽  
Melanie R. Keats ◽  
Davinder S. Jassal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Resistance Exercise ◽  
Breast Cancer Survivors ◽  
Cancer Therapeutics ◽  
Cardiovascular Complications ◽  
Increased Risk ◽  
Clinical Conditions ◽  
Exercise Guidelines ◽  
Dose Dependent

While developments in cancer therapeutics have greatly reduced morbidity and mortality in females with breast cancer, it comes at a cost of an increased risk of cardiovascular complications. In particular, anthracyclines, like doxorubicin, which are a mainstay of current chemotherapy regimens, are associated with dose-dependent cardiotoxicity. Exercise has been widely accepted as an effective intervention in reducing cardiovascular risk in a variety of different clinical conditions. However, the benefits of exercise in anthracycline-mediated cardiotoxicity are not clearly understood. First, this review discusses the pre-clinical studies which have elucidated the cardioprotective mechanisms of aerobic and resistance exercise in improving cardiovascular function in the setting of anthracycline treatment. Next, it aims to summarize the results of aerobic and resistance exercise clinical trials conducted in females with breast cancer who received anthracycline-based chemotherapy. The review further discusses the current exercise guidelines for women undergoing chemotherapy and contraindications for exercise. Finally, the review addresses gaps in research, specifically the need for further clinical trials to establish a recommended exercise prescription within this patient population.

scholarly journals Cancer treatment associated cardiac toxicities

2018 ◽  
Vol 7 (3) ◽  
pp. 353
Author(s):  
Eric Y. Chang ◽  
Aneese F. Chaudhry ◽  
Victoria Lopez ◽  
Sanjay R. Jain
Keyword(s):  
Cardiovascular Disease ◽  
Cancer Progression ◽  
Superior Vena ◽  
Survival Rates ◽  
Vena Cava ◽  
Cancer Therapeutics ◽  
Developed Countries ◽  
Cardiovascular Complications ◽  
Mortality And Morbidity ◽  
Vena Cava Syndrome

Cardiovascular disease remains the leading cause of mortality and morbidity in men and women both in the US and worldwide. With increased access to healthcare, it is predicted that life expectancies in developed countries will continue to rise and thus, lead to an increase in both cardiovascular disease and cancer. Similarly, improved survival rates in cancer patients have led to an increased awareness of the presence and potential worsening of cardiovascular disease in these patients. Cardiovascular complications due to side effects from cancer therapy or from cancer progression can be a common occurrence. Although recent advances in cancer therapeutics have led to improved survival rates and quality of life, the increase in life expectancy may be counteracted by the increased morbidity and mortality from progressive cardiac pathology. Examples of such complications include local invasion or distant metastatic spread, which can lead to superior vena cava syndrome, cardiac tamponade, or hyperviscosity syndromes. In addition, many chemo and radiation therapies can be directly toxic to the cardiovascular system. This review aims to discuss the potential cardiac toxicities of the most commonly used chemotherapeutics along with some strategies to manage these complex patients.

In Search of Novel Cancer Therapeutics: Assessing the NCI Natural Product Library against Ten Anti-Apoptotic Protein Targets

Planta Medica ◽  
2013 ◽  
Vol 79 (10) ◽  
Author(s):  
DB Divlianska ◽  
AE Wright ◽  
S Francis ◽  
MA Walters ◽  
CE Salomon ◽  
...  
Keyword(s):  
Natural Product ◽  
Cancer Therapeutics ◽  
Protein Targets ◽  
Apoptotic Protein ◽  
Natural Product Library

Update CACOCA Trial (cardiovascular complications of cancer treatment)

Pneumologie ◽  
2014 ◽  
Vol 68 (05) ◽  
Author(s):  
F Kocher ◽  
B Föger ◽  
M Fiegl ◽  
M Fridrik ◽  
G Gastl ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Cardiovascular Complications

Pregnancy-Related Cardiovascular Complications: Case Presentation and Review of Literature

2016 ◽  
Vol 19 (5) ◽  
pp. E248-E254 ◽  
Author(s):  
Hasan Baki Altinsoy ◽  
Ozkan Alatas ◽  
Salih Colak ◽  
Hakan Atalay ◽  
Omer Faruk Dogan
Keyword(s):  
Cardiac Surgery ◽  
Cesarean Section ◽  
Pregnant Women ◽  
Median Time ◽  
Artery Bypass ◽  
Prosthetic Heart Valve ◽  
Cardiovascular Complications ◽  
Time To Diagnosis ◽  
Valve Thrombosis ◽  
Placental Blood

Background: Cardiovascular complications that can cause severe catastrophic outcomes for both the mother and the fetus are rarely seen during pregnancy. Time to diagnosis is often delayed by a low degree of suspicion and atypical presentation. We report surgical strategies in three pregnant women with cardiovascular complications. Methods: A retrospective search from 2009 to 2016 identified three pregnant women who underwent urgent cardiac surgery. We used extracorporeal circulation (ECC) without cesarean section with careful follow-up of the fetuses during the perioperative and postoperative period. We used levosimendan as a potent inodilator in all patients to increase feto-placental blood flow and fetal heart rhythm.Results: Median time to diagnosis was 23.8 h (range 11.7-120 h) and median time from diagnosis to arrival in the operating theater was 9.8 h (range 7.4-19.8 h). One patient with prosthetic heart valve thrombosis underwent concomitant cesarean section prior to cardiac surgery. In a young pregnant woman who had spontaneous dissection of the left anterior descending artery, on-pump beating heart coronary artery bypass grafting was performed without cross clamping. Two and three months after surgery, cesarean sections were performed without any complication in two pregnant women.Conclusion: Because unusual cardiovascular complications are the main cause of maternal and/or fetus death during pregnancy, prompt and exact diagnosis is very important. Life-saving surgical strategy with the help of appropriate teams are necessary to optimize outcome for both mother and baby.

ANGPTL4 as Biomarker in Early Detection of Cardiovascular Complications in Diabetic Patients

2011 ◽  
Vol 3 (4) ◽  
pp. 16-19 ◽  
Author(s):  
Gamil M Abd-Allah ◽  
◽  
Fawkia E Zahran ◽  
Mohamed E Hassan ◽  
Hasan H Essobky
Keyword(s):  
Early Detection ◽  
Cardiovascular Complications ◽  
Diabetic Patients

The Role of Revascularisation in Patients Undergoing Non-cardiac Surgery

2010 ◽  
Vol 5 (1) ◽  
pp. 104
Author(s):  
Daniel S Menees ◽  
Eric R Bates ◽  
◽  
Keyword(s):  
Cardiac Surgery ◽  
Prediction Models ◽  
Cardiovascular Complications ◽  
Weight Of Evidence ◽  
Beta Blockade ◽  
Cardiac Morbidity ◽  
Increased Risk ◽  
Reduction Strategies ◽  
Artery Disease ◽  
Risk Reduction Strategies

Coronary artery disease (CAD) affects millions of US citizens. As the population ages, an increasing number of people with CAD are undergoing non-cardiac surgery and face significant peri-operative cardiac morbidity and mortality. Risk-prediction models can be used to help identify those patients at increased risk of peri-operative cardiovascular complications. Risk-reduction strategies utilising pharmacotherapy with beta blockade and statins have shown the most promise. Importantly, the benefit of prophylactic coronary revascularisation has not been demonstrated. The weight of evidence suggests reserving either percutaneous or surgical revascularisation in the pre-operative setting for those patients who would otherwise meet independent revascularisation criteria.

Sign in / Sign up

Export Citation Format

Share Document